Related Experiment Videos

Evidence-based statin prescription for cardiovascular protection in renal impairment

Fabio Fabbian1, Alfredo De Giorgi, Marco Pala

  • 1Department of Clinical and Experimental Medicine, Section of Clinica Medica, University of Ferrara, Azienda Ospedaliera-Universitaria S.Anna, Corso Giovecca, 203, 44123 Ferrara, Italy. f.fabbian@ospfe.it

Clinical and Experimental Nephrology
|May 11, 2011
PubMed

Insights

Statins effectively reduce cardiovascular risk in early chronic kidney disease (CKD) and renal transplant patients. While outcomes vary in later CKD stages, statin therapy offers a modifiable approach to managing dyslipidemia and preventing heart disease in specific patient groups.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in chronic kidney disease (CKD) patients.
  • Dyslipidemia is a significant CVD risk factor, and statins are established cardioprotective agents in the general population.
  • However, the efficacy of statin therapy in CKD patients remains under investigation due to trial exclusions and complex pathophysiology.

Purpose of the Study:

  • To evaluate the effectiveness of statins in preventing cardiovascular events across different stages of chronic kidney disease (CKD).
  • To determine the number of patients needed to treat (NNT) with statins for cardiovascular event prevention in various interventional trials involving CKD populations.

Main Methods:

  • Analysis of existing large-scale statin trials, including post-hoc analyses focusing on CKD subgroups.
  • Calculation of the number of patients needed to treat (NNT) to prevent one cardiovascular event.

Main Results:

  • Statins demonstrated reduced cardiovascular risk in early CKD and renal transplant recipients.
  • Trials involving haemodialysis patients showed less favorable outcomes.
  • Statins were more effective for secondary than primary CVD prevention in early CKD patients.

Conclusions:

  • Dyslipidemia is a modifiable risk factor for CVD in CKD.
  • Statins are effective in mitigating cardiovascular risk, particularly in the early stages of CKD.
  • Consideration of individual patient prognosis is crucial when prescribing statins for renal replacement therapy patients.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration01:28

Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration

Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area. This equation is...
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance01:25

Drug Dosing in Renal Diseases: Measurement of Serum Creatinine Concentration and Clearance

In healthy individuals, serum creatinine levels remain stable due to a balance between its constant production—primarily from muscle metabolism—and renal excretion. Creatinine is freely filtered by the glomeruli, making it a valuable marker for estimating renal function. When the glomerular filtration rate (GFR) decreases, the kidneys can only eliminate less creatinine, causing serum levels to rise.Serum creatinine concentration is widely used to estimate creatinine clearance (Clcr), a...